%0 Journal Article
%A Ben Khaled, Najib
%A Schulz, Christian
%A Alunni-Fabbroni, Marianna
%A Bronny, Kathrin
%A Jochheim, Leonie S
%A Kalali, Behnam
%A Öcal, Osman
%A Seidensticker, Max
%A Piseddu, Ignazio
%A Enssle, Stefan
%A Karin, Monika
%A Schneider, Julia S
%A Strasoldo-Graffemberg, Theresa
%A Koch, Nadine
%A Macke, Lukas
%A Reiter, Florian P
%A Lange, Christian M
%A Wang, Yinghong
%A De Toni, Enrico N
%A Gerhard, Markus
%A Mayerle, Julia
%A Ricke, Jens
%A Malfertheiner, Peter
%T Impact of Helicobacter pylori on Immune Checkpoint Inhibition in Hepatocellular Carcinoma: A Multicenter Study.
%J Digestion
%V 106
%N 4
%@ 0012-2823
%C Basel
%I Karger
%M DKFZ-2025-00400
%P 303-313
%D 2025
%Z 2025;106(4):303-313
%X Immunomodulating effects of Helicobacter pylori (H. pylori) have been shown to inhibit antitumor immunity. Resistance to immune checkpoint inhibitor (ICI)-based therapies is common among patients with hepatocellular carcinoma (HCC). This study aimed to assess the effect of H. pylori on the outcomes of ICI in patients with HCC.We conducted a multicenter study in patients with HCC across a broad range of treatments. Patients received either ICI-based combination regimens or sorafenib-based therapy. H. pylori serostatus and virulence factors were determined and correlated with overall survival (OS), progression-free survival (PFS), and safety across the treatment modalities.180 patients with HCC were included; among these, 64 were treated with ICI-based regimen and 116 with sorafenib-based regimen. In patients treated with ICI, median OS was shorter in H. pylori-positive patients (10.9 months in H. pylori-positive vs. 18.3 months; p = 0.0384). H. pylori positivity was associated with a shorter PFS in ICI recipients (3.9 months vs. 6.8 months, p = 0.0499). In patients treated with sorafenib, median OS was not shorter among H. pylori-positive patients (13.4 months in H. pylori-positive vs. 10.6 months; p = 0.3353). Immune-related adverse events and rates of gastrointestinal bleeding were comparable between H. pylori-positive and -negative patients.H. pylori seropositivity was linked to poorer outcomes in patients with HCC treated with ICI. This association was not observed among patients receiving sorafenib-based therapies.
%K Helicobacter pylori (Other)
%K Hepatocellular carcinoma (Other)
%K Immune checkpoint inhibitor (Other)
%K Immunotherapy (Other)
%K Resistance (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39970893
%R 10.1159/000542847
%U https://inrepo02.dkfz.de/record/298980